NervGen Pharma GAAP EPS of -$0.11

May 12, 2022 8:57 AM ETNervGen Pharma Corp. (NGENF), NGEN:CABy: Pranav Ghumatkar, SA News Editor35 Comments
  • NervGen Pharma press release (OTCQX:NGENF): Q1 GAAP EPS of -$0.11.
  • NervGen had cash and investments of $12.8 million as of March 31, 2022, compared to $5.0 million as of March 31, 2021. The net cash burn for Q1 2022 from operating activities was approximately $4.2 million.

Recommended For You

Comments (35)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.